APW
NTLA icon

Aventura Private Wealth’s Intellia Therapeutics NTLA Stock Holding History

Aventura Private Wealth’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.7K Hold
1,990
– – 0.01% 394
2026
Q1 		$25.5K Buy
+1,990
New +$25.3K 0.01% 412

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Aventura Private Wealth's NTLA Position: Q2 2026 in Review

Aventura Private Wealth held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 1,990 shares worth $33.7K. The position accounts for 0.01% of the portfolio, ranked #394.

Aventura Private Wealth first reported a position in NTLA in Q1 2026 and has held it in 2 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Aventura Private Wealth held 1,990 shares of Intellia Therapeutics worth $33.7K as of Q2 2026.
  • Aventura Private Wealth left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up 0.01% of Aventura Private Wealth's portfolio in Q2 2026, its #394 holding.
  • Aventura Private Wealth first reported a position in Intellia Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Aventura Private Wealth's 13F filing for Q2 2026, filed 15 Jul 2026.